Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: A phase I study

D. I. Rosenthal, R. J. Sinard, O. Okani, J. Corak, D. Kavanaugh, B. Kamen, F. M. Vuitch, A. F. Gazdar, J. Griener, E. P. Frenkel, D. P. Carbone

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous- infusion (24 hr/d, 7 d/wk, 7-week total) intravenous paclitaxel (Taxol; Bristol-Mayers Squibb Company, Princeton, NJ) combined with standard curative radiotherapy (RT) for previously untreated, locally advanced head and neck squamous cell cancers. Eligible patients have squamous cell cancers of the head and neck with expected 5-year survival rates of ≤25%; a good performance status; adequate hematologic, hepatic, and renal functions; and no distant metastases. All patients receive 70 Gy megavoltage RT in 7 weeks (2 Gy/d x 5 d/wk). Paclitaxel is delivered by protracted venous infusion starting 48 hours before RT and continuing for its duration. Biopsies for cell-cycle distribution analyses and paclitaxel tissue levels are obtained, if possible, before beginning paclitaxel and after 48 hours just before RT begins. The dose of paclitaxel is escalated in cohorts of three patients. Eighteen patients are evaluable for toxicity. Treatment has been completed through the 6.5 mg/m2/d dose level and is ongoing at 10.5 mg/m2/d. There has been no dose-limiting toxicity thus far. With the exception of anemia, toxicity is commensurate with what would be expected from RT alone. A slowly progressive normocytic anemia with no renal dysfunction was found to be associated with an acquired hypoerythropoietin state. Tumor biopsies have suggested the possibility of paclitaxel-induced mitotic arrest. This therapy is feasible and has been well tolerated through current dose levels with no dose-limiting toxicity. There is a suggestion of biologic activity evidenced by the anemia and the possibility of alteration in cell-cycle distributions. Dose escalation is ongoing.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number6 SUPPL. 19
StatePublished - 1997

Fingerprint

Squamous Cell Neoplasms
Head and Neck Neoplasms
Paclitaxel
Radiotherapy
Head
Anemia
Cell Cycle
Kidney
Biopsy
National Cancer Institute (U.S.)
Survival Rate
Pharmacokinetics
Neoplasm Metastasis
Liver
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Rosenthal, D. I., Sinard, R. J., Okani, O., Corak, J., Kavanaugh, D., Kamen, B., ... Carbone, D. P. (1997). Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: A phase I study. Seminars in Oncology, 24(6 SUPPL. 19).

Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer : A phase I study. / Rosenthal, D. I.; Sinard, R. J.; Okani, O.; Corak, J.; Kavanaugh, D.; Kamen, B.; Vuitch, F. M.; Gazdar, A. F.; Griener, J.; Frenkel, E. P.; Carbone, D. P.

In: Seminars in Oncology, Vol. 24, No. 6 SUPPL. 19, 1997.

Research output: Contribution to journalArticle

Rosenthal, DI, Sinard, RJ, Okani, O, Corak, J, Kavanaugh, D, Kamen, B, Vuitch, FM, Gazdar, AF, Griener, J, Frenkel, EP & Carbone, DP 1997, 'Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: A phase I study', Seminars in Oncology, vol. 24, no. 6 SUPPL. 19.
Rosenthal, D. I. ; Sinard, R. J. ; Okani, O. ; Corak, J. ; Kavanaugh, D. ; Kamen, B. ; Vuitch, F. M. ; Gazdar, A. F. ; Griener, J. ; Frenkel, E. P. ; Carbone, D. P. / Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer : A phase I study. In: Seminars in Oncology. 1997 ; Vol. 24, No. 6 SUPPL. 19.
@article{93def5002b944910ac9b741ccc0ec21f,
title = "Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: A phase I study",
abstract = "The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous- infusion (24 hr/d, 7 d/wk, 7-week total) intravenous paclitaxel (Taxol; Bristol-Mayers Squibb Company, Princeton, NJ) combined with standard curative radiotherapy (RT) for previously untreated, locally advanced head and neck squamous cell cancers. Eligible patients have squamous cell cancers of the head and neck with expected 5-year survival rates of ≤25{\%}; a good performance status; adequate hematologic, hepatic, and renal functions; and no distant metastases. All patients receive 70 Gy megavoltage RT in 7 weeks (2 Gy/d x 5 d/wk). Paclitaxel is delivered by protracted venous infusion starting 48 hours before RT and continuing for its duration. Biopsies for cell-cycle distribution analyses and paclitaxel tissue levels are obtained, if possible, before beginning paclitaxel and after 48 hours just before RT begins. The dose of paclitaxel is escalated in cohorts of three patients. Eighteen patients are evaluable for toxicity. Treatment has been completed through the 6.5 mg/m2/d dose level and is ongoing at 10.5 mg/m2/d. There has been no dose-limiting toxicity thus far. With the exception of anemia, toxicity is commensurate with what would be expected from RT alone. A slowly progressive normocytic anemia with no renal dysfunction was found to be associated with an acquired hypoerythropoietin state. Tumor biopsies have suggested the possibility of paclitaxel-induced mitotic arrest. This therapy is feasible and has been well tolerated through current dose levels with no dose-limiting toxicity. There is a suggestion of biologic activity evidenced by the anemia and the possibility of alteration in cell-cycle distributions. Dose escalation is ongoing.",
author = "Rosenthal, {D. I.} and Sinard, {R. J.} and O. Okani and J. Corak and D. Kavanaugh and B. Kamen and Vuitch, {F. M.} and Gazdar, {A. F.} and J. Griener and Frenkel, {E. P.} and Carbone, {D. P.}",
year = "1997",
language = "English (US)",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 SUPPL. 19",

}

TY - JOUR

T1 - Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer

T2 - A phase I study

AU - Rosenthal, D. I.

AU - Sinard, R. J.

AU - Okani, O.

AU - Corak, J.

AU - Kavanaugh, D.

AU - Kamen, B.

AU - Vuitch, F. M.

AU - Gazdar, A. F.

AU - Griener, J.

AU - Frenkel, E. P.

AU - Carbone, D. P.

PY - 1997

Y1 - 1997

N2 - The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous- infusion (24 hr/d, 7 d/wk, 7-week total) intravenous paclitaxel (Taxol; Bristol-Mayers Squibb Company, Princeton, NJ) combined with standard curative radiotherapy (RT) for previously untreated, locally advanced head and neck squamous cell cancers. Eligible patients have squamous cell cancers of the head and neck with expected 5-year survival rates of ≤25%; a good performance status; adequate hematologic, hepatic, and renal functions; and no distant metastases. All patients receive 70 Gy megavoltage RT in 7 weeks (2 Gy/d x 5 d/wk). Paclitaxel is delivered by protracted venous infusion starting 48 hours before RT and continuing for its duration. Biopsies for cell-cycle distribution analyses and paclitaxel tissue levels are obtained, if possible, before beginning paclitaxel and after 48 hours just before RT begins. The dose of paclitaxel is escalated in cohorts of three patients. Eighteen patients are evaluable for toxicity. Treatment has been completed through the 6.5 mg/m2/d dose level and is ongoing at 10.5 mg/m2/d. There has been no dose-limiting toxicity thus far. With the exception of anemia, toxicity is commensurate with what would be expected from RT alone. A slowly progressive normocytic anemia with no renal dysfunction was found to be associated with an acquired hypoerythropoietin state. Tumor biopsies have suggested the possibility of paclitaxel-induced mitotic arrest. This therapy is feasible and has been well tolerated through current dose levels with no dose-limiting toxicity. There is a suggestion of biologic activity evidenced by the anemia and the possibility of alteration in cell-cycle distributions. Dose escalation is ongoing.

AB - The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous- infusion (24 hr/d, 7 d/wk, 7-week total) intravenous paclitaxel (Taxol; Bristol-Mayers Squibb Company, Princeton, NJ) combined with standard curative radiotherapy (RT) for previously untreated, locally advanced head and neck squamous cell cancers. Eligible patients have squamous cell cancers of the head and neck with expected 5-year survival rates of ≤25%; a good performance status; adequate hematologic, hepatic, and renal functions; and no distant metastases. All patients receive 70 Gy megavoltage RT in 7 weeks (2 Gy/d x 5 d/wk). Paclitaxel is delivered by protracted venous infusion starting 48 hours before RT and continuing for its duration. Biopsies for cell-cycle distribution analyses and paclitaxel tissue levels are obtained, if possible, before beginning paclitaxel and after 48 hours just before RT begins. The dose of paclitaxel is escalated in cohorts of three patients. Eighteen patients are evaluable for toxicity. Treatment has been completed through the 6.5 mg/m2/d dose level and is ongoing at 10.5 mg/m2/d. There has been no dose-limiting toxicity thus far. With the exception of anemia, toxicity is commensurate with what would be expected from RT alone. A slowly progressive normocytic anemia with no renal dysfunction was found to be associated with an acquired hypoerythropoietin state. Tumor biopsies have suggested the possibility of paclitaxel-induced mitotic arrest. This therapy is feasible and has been well tolerated through current dose levels with no dose-limiting toxicity. There is a suggestion of biologic activity evidenced by the anemia and the possibility of alteration in cell-cycle distributions. Dose escalation is ongoing.

UR - http://www.scopus.com/inward/record.url?scp=17144452716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144452716&partnerID=8YFLogxK

M3 - Article

C2 - 9427270

AN - SCOPUS:17144452716

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 SUPPL. 19

ER -